RYTM - リズム・ファ―マシュ―ティカルズ (Rhythm Pharmaceuticals Inc.) リズム・ファ―マシュ―ティカルズ

 RYTMのチャート


 RYTMの企業情報

symbol RYTM
会社名 Rhythm Pharmaceuticals Inc (リズム・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 リズム・ファーマシューティカルズ(Rhythm Pharmaceuticals Inc.)はバイオ医薬品会社である。同社は、生命を脅かす代謝障害をもたらす希少な遺伝的欠陥の治療用ペプチド治療薬の開発と商品化に注力する。同社のリードペプチド製品候補は、稀な遺伝性肥満疾患の治療用のメラノコルチン-4受容体、またはMC4Rアゴニストというセメラノイドである。セルトメラノイドは、メラノコルチン-4またはMC4経路欠損の治療用補充療法として役立つ。MC4経路欠損は、体内の満腹信号およびエネルギー恒常性の崩壊をもたらし、ひいては飢餓・肥満の激しい感情につながる。また、6つの単一の遺伝子関連、または一遺伝子性のMC4経路欠損プロオピオメラノコルチン、またはPOMC、レプチン受容体、またはLepR、Bardet-Biedl症候群、Alstrom症候群、POMCヘテロ接合体及びPOMCエピジェネティック障害に関連する肥満に重点を置いた。   リズム・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、生命を脅かす代謝障害を引き起こす遺伝的疾患に対するペプチド治療薬の開発・商業化に従事する。主な新薬候補はセメラノイド(RM-493)で、MC4経路の欠損によって起こる稀な遺伝的肥満疾患の治療に使用され、6種類の疾患において評価する。本社所在地はマサチュ―セッツ州ボストン。   Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
本社所在地 500 Boylston Street 11th Floor Boston MA 02116 USA
代表者氏名 David P. Meeker David P. Meeker
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-264-4280
設立年月日 41306
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数
url www.rhythmtx.com
nasdaq_url https://www.nasdaq.com/symbol/rytm
adr_tso
EBITDA EBITDA(百万ドル) -51.05400
終値(lastsale) 26.23
時価総額(marketcap) 896413843.51
時価総額 時価総額(百万ドル) 950.75230
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 663.19830
当期純利益 当期純利益(百万ドル) -52.91900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Rhythm Pharmaceuticals Inc revenues was not reported. Net loss applicable to common stockholders increased 99% to $30.9M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.60 to -$1.12.

 RYTMのテクニカル分析


 RYTMのニュース

   Rhythm Pharmaceuticals prices stock offering; shares down 11% after hours  2019/10/16 04:10:23 Seeking Alpha
Rhythm Pharmaceuticals (RYTM) prices its public offering of 8.11M common shares at $18.50/share. The greenshoe option is for another 1.22M common shares Cl
   Rhythm Rips Higher After Obesity Drug Aces Late-Stage Trials  2019/08/07 13:49:29 Benzinga
Shares of the thinly traded small-cap biotech Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) were rallying by more than 15% Wednesday. What Happened Boston-based Rhythm , which focuses on therapies for rare genetic disorders of obesity, announced positive topline results from two pivotal Phase 3 trials that evaluated its setmelanotide for the treatment of pro-opiomelanocortin, or POMC, and leptin receptor, or LEPR, deficiency obesities. Setmelanotide is Rhythm's melanocortin-4 receptor agonist. The company said both studies met their primary endpoints and all key secondary endpoints, showing a statistically significant and clinically meaningfully effect … Full story available on Benzinga.com
   The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster  2019/07/31 11:06:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Medpace Holdings Inc (NASDAQ: MEDP )(reported strong second-quarter results ) Novocure Ltd (NASDAQ: NVCR ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 30) Alimera Sciences Inc (NASDAQ: ALIM )(reacted to second-quarter results) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Equillium Inc (NASDAQ: EQ ) Medtronic PLC (NYSE: MDT ) Obseva SA (NASDAQ: OBSV ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Stocks In Focus Roche Extends Offer Period For Spark Buy Once Again Roche Holdings AG Basel ADR (OTC: RHHBY ) and Spark Therapeutics Inc (NASDAQ: ONCE ) announced Wednesday Roche has extended the offering period for its previously announced tender offer to buy all outstanding shares of Spark for $114.50 …
   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.
   Rhythm Pharmaceuticals misses by $0.08  2019/05/03 12:38:31 Seeking Alpha
Rhythm Pharmaceuticals (RYTM): Q1 GAAP EPS of -$0.84misses by $0.08. Cash and cash equivalents of $42.02M Press Release
   Rhythm Pharmaceuticals prices stock offering; shares down 11% after hours  2019/10/16 04:10:23 Seeking Alpha
Rhythm Pharmaceuticals (RYTM) prices its public offering of 8.11M common shares at $18.50/share. The greenshoe option is for another 1.22M common shares Cl
   Rhythm Rips Higher After Obesity Drug Aces Late-Stage Trials  2019/08/07 13:49:29 Benzinga
Shares of the thinly traded small-cap biotech Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) were rallying by more than 15% Wednesday. What Happened Boston-based Rhythm , which focuses on therapies for rare genetic disorders of obesity, announced positive topline results from two pivotal Phase 3 trials that evaluated its setmelanotide for the treatment of pro-opiomelanocortin, or POMC, and leptin receptor, or LEPR, deficiency obesities. Setmelanotide is Rhythm's melanocortin-4 receptor agonist. The company said both studies met their primary endpoints and all key secondary endpoints, showing a statistically significant and clinically meaningfully effect … Full story available on Benzinga.com
   The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster  2019/07/31 11:06:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Medpace Holdings Inc (NASDAQ: MEDP )(reported strong second-quarter results ) Novocure Ltd (NASDAQ: NVCR ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 30) Alimera Sciences Inc (NASDAQ: ALIM )(reacted to second-quarter results) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Equillium Inc (NASDAQ: EQ ) Medtronic PLC (NYSE: MDT ) Obseva SA (NASDAQ: OBSV ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Stocks In Focus Roche Extends Offer Period For Spark Buy Once Again Roche Holdings AG Basel ADR (OTC: RHHBY ) and Spark Therapeutics Inc (NASDAQ: ONCE ) announced Wednesday Roche has extended the offering period for its previously announced tender offer to buy all outstanding shares of Spark for $114.50 …
   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.
   Rhythm Pharmaceuticals misses by $0.08  2019/05/03 12:38:31 Seeking Alpha
Rhythm Pharmaceuticals (RYTM): Q1 GAAP EPS of -$0.84misses by $0.08. Cash and cash equivalents of $42.02M Press Release
   Rhythm Pharmaceuticals prices stock offering; shares down 11% after hours  2019/10/16 04:10:23 Seeking Alpha
Rhythm Pharmaceuticals (RYTM) prices its public offering of 8.11M common shares at $18.50/share. The greenshoe option is for another 1.22M common shares Cl
   Rhythm Rips Higher After Obesity Drug Aces Late-Stage Trials  2019/08/07 13:49:29 Benzinga
Shares of the thinly traded small-cap biotech Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) were rallying by more than 15% Wednesday. What Happened Boston-based Rhythm , which focuses on therapies for rare genetic disorders of obesity, announced positive topline results from two pivotal Phase 3 trials that evaluated its setmelanotide for the treatment of pro-opiomelanocortin, or POMC, and leptin receptor, or LEPR, deficiency obesities. Setmelanotide is Rhythm's melanocortin-4 receptor agonist. The company said both studies met their primary endpoints and all key secondary endpoints, showing a statistically significant and clinically meaningfully effect … Full story available on Benzinga.com
   The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster  2019/07/31 11:06:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on July 30) Acasti Pharma Inc (NASDAQ: ACST ) ANI Pharmaceuticals Inc Common Stock (NASDAQ: ANIP ) Arcturus Therapeutics Ltd (NASDAQ: ARCT ) Hologic, Inc. (NASDAQ: HOLX ) Insulet Corporation (NASDAQ: PODD ) Medpace Holdings Inc (NASDAQ: MEDP )(reported strong second-quarter results ) Novocure Ltd (NASDAQ: NVCR ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on July 30) Alimera Sciences Inc (NASDAQ: ALIM )(reacted to second-quarter results) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Aquestive Therapeutics Inc (NASDAQ: AQST ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Equillium Inc (NASDAQ: EQ ) Medtronic PLC (NYSE: MDT ) Obseva SA (NASDAQ: OBSV ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) TRACON Pharmaceuticals Inc (NASDAQ: TCON ) Trevi Therapeutics Inc (NASDAQ: TRVI ) Zimmer Biomet Holdings Inc (NYSE: ZBH ) Stocks In Focus Roche Extends Offer Period For Spark Buy Once Again Roche Holdings AG Basel ADR (OTC: RHHBY ) and Spark Therapeutics Inc (NASDAQ: ONCE ) announced Wednesday Roche has extended the offering period for its previously announced tender offer to buy all outstanding shares of Spark for $114.50 …
   The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana  2019/06/12 11:34:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Hemispherx BioPharma, Inc (NYSE: HEB )(started trading on a 1-for-44 reverse split adjusted basis) Down In The Dumps (Biotech stocks hitting 52-week lows on June 11) Acer Therapeutics Inc (NASDAQ: ACER ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CymaBay Therapeutics Inc (NASDAQ: CBAY )( reported negative mid-stage trial results for its investigational NASH candidate seladelpar) Endo International PLC (NASDAQ: ENDP ) GENFIT S A/ADR (NASDAQ: GNFT )(moved in sympathy with CymaBay) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Novavax, Inc. (NASDAQ: NVAX ) Puma Biotechnology Inc (NASDAQ: PBYI ) RA Medical Systems Inc (NYSE: RMED ) Rhythm Pharmaceuticals Inc (NASDAQ: RYTM ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) TherapeuticsMD Inc (NASDAQ: TXMD ) Unum Therapeutics Inc (NASDAQ: UMRX ) Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ) Stock In Focus Nuvectra Files For Approval For Spinal Cord Stimulation System Medical device company Nuvectra Corp (NASDAQ: NVTR ) filed its regulatory submission with the FDA for it full-body MR-conditional approval for its Algovita spinal cord stimulation, or SCS, system.
   Rhythm Pharmaceuticals misses by $0.08  2019/05/03 12:38:31 Seeking Alpha
Rhythm Pharmaceuticals (RYTM): Q1 GAAP EPS of -$0.84misses by $0.08. Cash and cash equivalents of $42.02M Press Release

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 リズム・ファ―マシュ―ティカルズ RYTM Rhythm Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)